TY - JOUR
T1 - GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
AU - The ATL Working Group of the Japanese Society for Hematopoietic Cell Transplantation
AU - Muranushi, Hiroyuki
AU - Shindo, Takero
AU - Hishizawa, Masakatsu
AU - Tokunaga, Masahito
AU - Wake, Atsushi
AU - Nakano, Nobuaki
AU - Eto, Tetsuya
AU - Hidaka, Michihiro
AU - Choi, Ilseung
AU - Miyamoto, Toshihiro
AU - Uchida, Naoyuki
AU - Moriuchi, Yukiyoshi
AU - Miyazaki, Yasuhiko
AU - Fukuda, Takahiro
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Yoshimitsu, Makoto
AU - Ishida, Takashi
AU - Utsunomiya, Atae
AU - Kato, Koji
AU - Suzumiya, Junji
AU - Tobai, Tomomi
AU - Nakase, Koichi
AU - Nawa, Yuichiro
AU - Hishizawa, Masakatsu
AU - Fukushima, Takuya
AU - Wake, Atsushi
AU - Choi, Ilseung
AU - Asakura, Yoshitaka
AU - Nakano, Nobuaki
AU - Fujiwara, Hiroshi
AU - Machida, Shinichiro
AU - Sawayama, Yasushi
AU - Inoue, Yoshitaka
AU - Imada, Kazunori
AU - Yoshida, Isao
AU - Fuji, Shigeo
AU - Shindo, Takero
AU - Tokunaga, Masahito
AU - Muranushi, Hiroyuki
AU - Morishima, Satoko
AU - Tomori, Shohei
AU - Iemura, Tomoki
AU - Shimizu, Takuya
AU - Morita-Fujita, Mari
AU - Kato, Koji
N1 - Funding Information:
Acknowledgements We thank all the physicians and data managers at the participating institutions who contributed valuable data on transplantation for ATL to the JSHCT. We also thank the members of the data management committees of the JSHCT and the ATL working group for their assistance. The members of the ATL working group are listed below. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from AMED, the Japan Agency for Medical Research and Development (grant number 19ek0510023h0002). This work was presented as an abstract at the 62nd annual meeting of the American Society of Hematology, Orlando, FL, December 7th, 2019.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/1
Y1 - 2021/1
N2 - The outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for adult T-cell leukemia/lymphoma (ATL) is still unsatisfactory. To illustrate the advantages and disadvantages of each donor source, we performed a nationwide retrospective study of graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) of patients with allo-HSCT-treated ATL. One-year GRFS did not significantly differ between patients who received related bone marrow transplantation (R-BMT; 26%, n = 117), related peripheral blood stem cell transplantation (R-PBSCT; 22%, n = 225), unrelated bone marrow transplantation (UR-BMT; 26%, n = 619), and cord blood transplantation (CBT; 21%, n = 359; p = 0.09). This was attributable to a low incidence of systemically-treated chronic GVHD after CBT (9% at 1 year) and reduced non-GVHD/relapse mortality after R-PBSCT (9% at 1 year). Among patients transplanted in complete remission (CR), 1-year overall survival after CBT (52%, n = 132) was not inferior to that after R-BMT (55%, n = 51), R-PBSCT (57%, n = 79), and UR-BMT (58%, n = 280; p = 0.15), and relapse rates were equivalent among the four sources (p = 0.19). Our results suggest that all donor sources are feasible for CR patients and that GRFS provides important clues toward optimizing allo-HSCT for ATL.
AB - The outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for adult T-cell leukemia/lymphoma (ATL) is still unsatisfactory. To illustrate the advantages and disadvantages of each donor source, we performed a nationwide retrospective study of graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) of patients with allo-HSCT-treated ATL. One-year GRFS did not significantly differ between patients who received related bone marrow transplantation (R-BMT; 26%, n = 117), related peripheral blood stem cell transplantation (R-PBSCT; 22%, n = 225), unrelated bone marrow transplantation (UR-BMT; 26%, n = 619), and cord blood transplantation (CBT; 21%, n = 359; p = 0.09). This was attributable to a low incidence of systemically-treated chronic GVHD after CBT (9% at 1 year) and reduced non-GVHD/relapse mortality after R-PBSCT (9% at 1 year). Among patients transplanted in complete remission (CR), 1-year overall survival after CBT (52%, n = 132) was not inferior to that after R-BMT (55%, n = 51), R-PBSCT (57%, n = 79), and UR-BMT (58%, n = 280; p = 0.15), and relapse rates were equivalent among the four sources (p = 0.19). Our results suggest that all donor sources are feasible for CR patients and that GRFS provides important clues toward optimizing allo-HSCT for ATL.
UR - http://www.scopus.com/inward/record.url?scp=85087863544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087863544&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-00996-y
DO - 10.1038/s41409-020-00996-y
M3 - Article
C2 - 32665675
AN - SCOPUS:85087863544
SN - 0268-3369
VL - 56
SP - 155
EP - 166
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 1
ER -